In contrast to earlier studies that showed a beneficial influence of rituximab on HLA antibody production after kidney transplantation, a recent report by Ashimine et al. questions such an effect. That previous studies included presensitized patients who are more prone to antibody development, might explain this controversy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sellares, J. et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am. J. Transplant. 12, 388–399 (2012).
Becker, L. E., Süsal, C. & Morath, C. Kidney transplantation across HLA and ABO antibody barriers. Curr. Opin. Organ Transplant. 18, 445–454 (2013).
Jordan, S. C., Kahwaji, J., Toyoda, M. & Vo, A. B-cell immunotherapeutics: emerging roles in solid organ transplantation. Curr. Opin. Organ Transplant. 16, 416–424 (2011).
Ashimine, S. et al. Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation. Kidney Int. http://dx.doi.org/10.1038/ki.2013.291.
Wiebe, C. et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am. J. Transplant. 12, 1157–1167 (2012).
Kohei, N., Hirai, T., Omoto, K., Ishida, H. & Tanabe, K. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am. J. Transplant. 12, 469–476 (2012).
Stegall, M. D., Gloor, J., Winters, J. L., Moore, S. B. & Degoey, S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am. J. Transplant. 6, 346–351 (2006).
Vo, A. A. et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med. 359, 242–251 (2008).
Morath, C. et al. An integrative approach for the transplantation of high-risk sensitized patients. Transplantation 90, 645–653 (2010).
Tyden, G., Ekberg, H., Tufveson, G. & Mjornstedt, L. A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: a 3-year follow-up. Transplantation 94, e21–e22 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Morath, C., Süsal, C. Rituximab induction only for sensitized kidney recipients?. Nat Rev Nephrol 9, 703–705 (2013). https://doi.org/10.1038/nrneph.2013.230
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2013.230
